6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

450, 5th Street

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of January, 2006

Daiichi Sankyo Company, Limited

(Translation of registrant’s name into English)

5-1, Nihonbashi 3-chome

Chuo-ku, Tokyo 103-8426

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  þ        Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨        No  þ

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨        No  þ

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨        No  þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DAIICHI SANKYO COMPANY, LIMITED
DATE: January 24, 2006	By:	/s/ Takashi Shoda
	Name:	Takashi Shoda
	Title:	President and Representative Director

EXHIBIT INDEX

Exhibit Number		Description of Exhibit
99.1	—	Press Release: “The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg Receives Approval for Manufacture”

EX-99.1

Exhibit 99.1

For Immediate Release

DAIICHI SANKYO COMPANY, LIMITED

Lead Chemical Co., Ltd.

The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug

Loxonin Poultice 100mg Receives Approval for Manufacture

Tokyo, January 23, 2006 — The percutaneous absorption-type analgesic and anti-inflammatory preparation Loxonin poultice 100mg (generic name: loxoprofen sodium) which was jointly developed by Lead Chemical Co., Ltd. (hereafter Lead Chemical; President: Masao Mori; Headquarters: Toyama City, Toyama Prefecture) and a DAIICHI SANKYO COMPANY, LIMITED group subsidiary Sankyo Co., Ltd. (hereafter Sankyo; President: Yasuhiro Ikegami; Headquarters: Tokyo) has been approved for manufacture on January 23. Among poultice preparations containing nonsteroidal anti-inflammatory drugs (NSAIDs), it is the first poultice for usage once per day to be granted approval for manufacture.

Loxonin poultice is a hydrophilic preparation containing the same constituents as Loxonin pills and Loxonin powder, which is one of the leading brands among orally administered analgesic and anti-inflammatory drugs in Japan. As it is applied once per day, we expect there will be an improvement in user compliance.

We are confident that this new addition to the Loxonin brand, which is a long-standing top brand in the Japanese market, will further contribute to analgesic and anti-inflammatory drug treatment. This preparation is scheduled to be manufactured by Lead Chemical and sold by Sankyo.

For additional information, please contact:

DAIICHI SANKYO COMPANY, LIMITED

Corporate Communications Department

3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8426, Japan

Tel: 03-6225-1126

Fax: 03-6225-1132

Lead Chemical Co., Ltd.

Himata 77-3

Toyama City, Toyama Prefecture 930-0912, Japan